CAT

901.64

-1.14%↓

294.86

-0.88%↓

GEV.US

1,062.71

-0.85%↓

RTX

178.16

-0.31%↓

240.61

+1.55%↑

CAT

901.64

-1.14%↓

294.86

-0.88%↓

GEV.US

1,062.71

-0.85%↓

RTX

178.16

-0.31%↓

240.61

+1.55%↑

CAT

901.64

-1.14%↓

294.86

-0.88%↓

GEV.US

1,062.71

-0.85%↓

RTX

178.16

-0.31%↓

240.61

+1.55%↑

CAT

901.64

-1.14%↓

294.86

-0.88%↓

GEV.US

1,062.71

-0.85%↓

RTX

178.16

-0.31%↓

240.61

+1.55%↑

CAT

901.64

-1.14%↓

294.86

-0.88%↓

GEV.US

1,062.71

-0.85%↓

RTX

178.16

-0.31%↓

240.61

+1.55%↑

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Cerrado

1.46

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.45

Máximo

1.48

Métricas clave
By Trading Economics
Ingresos	-1.5M -19M
Ventas	1.7M 1.5M
BPA	-0.06
Margen de beneficios	-1,250.946
Empleados	116
EBITDA	-987K -17M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+687.07% upside

Dividendos
By Dow Jones
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-125M 501M
Apertura anterior	1.46
Cierre anterior	1.46

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.6818 / 0.74 Soporte y Resistencia

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2026, 22:54 UTC

Ganancias

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 may 2026, 23:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 may 2026, 23:51 UTC

Charlas de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 may 2026, 23:17 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 may 2026, 23:16 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 may 2026, 23:15 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 may 2026, 23:14 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 may 2026, 23:02 UTC

Charlas de Mercado

Ganancias

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 may 2026, 22:59 UTC

Charlas de Mercado

Ganancias

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 may 2026, 22:24 UTC

Ganancias

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Revenue Growth 47%>XRO.AU

13 may 2026, 22:22 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 may 2026, 22:18 UTC

Ganancias

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 may 2026, 22:16 UTC

Ganancias

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 may 2026, 22:13 UTC

Ganancias

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 may 2026, 22:12 UTC

Ganancias

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 may 2026, 22:09 UTC

Ganancias

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 may 2026, 22:00 UTC

Ganancias

Cisco to Shed Jobs for All-In AI Push -- Update

13 may 2026, 21:11 UTC

Ganancias

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

687.07% repunte

Estimación a 12 Meses

Media 11.57 USD 687.07%

Máximo 22 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6818 / 0.74Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.